User menu

Data-driven risk identification in phase III clinical trials using central statistical monitoring

Bibliographic reference Timmermans, Catherine ; Venet, David ; Burzykowski, Tomasz. Data-driven risk identification in phase III clinical trials using central statistical monitoring. In: International Journal of Clinical Oncology, Vol. 21, p. 38-45 (2016)
Permanent URL
  1. European Commission (2005) Commission directive 2005/28/EC. Off J Eur Union L91:13–19
  2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996) Guidelines for good clinical practices E6(R1). . Accessed 27 March 2015
  3. U.S. Department of Health and Human Services, Food and Drug Administration (2013) Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. . Accessed 20 February 2015
  4. Duley Lelia, Antman Karen, Arena Joseph, Avezum Alvaro, Blumenthal Mel, Bosch Jackie, Chrolavicius Sue, Li Timoa, Ounpuu Stephanie, Perez Analia Cristina, Sleight Peter, Svard Robbyna, Temple Robert, Tsouderous Yannis, Yunis Carla, Yusuf Salim, Specific barriers to the conduct of randomized trials, 10.1177/1740774507087704
  5. De Sourabh, Hybrid approaches to clinical trial monitoring: Practical alternatives to 100% source data verification, 10.4103/2229-3485.83226
  6. Tudur Smith Catrin, Stocken Deborah D., Dunn Janet, Cox Trevor, Ghaneh Paula, Cunningham David, Neoptolemos John P., The Value of Source Data Verification in a Cancer Clinical Trial, 10.1371/journal.pone.0051623
  7. Buyse M (2014) Centralized statistical monitoring as a way to improve the quality of clinical trials. Appl Clin Trials.
  8. Bakobaki Julie M, Rauchenberger Mary, Joffe Nicola, McCormack Sheena, Stenning Sally, Meredith Sarah, The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial, 10.1177/1740774511427325
  9. Morrison Briggs W, Cochran Chrissy J, White Jennifer Giangrande, Harley Joan, Kleppinger Cynthia F, Liu An, Mitchel Jules T, Nickerson David F, Zacharias Cynthia R, Kramer Judith M, Neaton James D, Monitoring the quality of conduct of clinical trials: a survey of current practices, 10.1177/1740774511402703
  10. European Medicines Agency (2011). Reflection paper on risk based quality management in clinical trials. EMA/INS/GCP/394194/2011. . Accessed 20 February 2015
  11. Baigent Colin, Harrell Frank E, Buyse Marc, Emberson Jonathan R, Altman Douglas G, Ensuring trial validity by data quality assurance and diversification of monitoring methods, 10.1177/1740774507087554
  12. George Stephen L, Buyse Marc, Data fraud in clinical trials, 10.4155/cli.14.116
  13. Venet David, Doffagne Erik, Burzykowski Tomasz, Beckers François, Tellier Yves, Genevois-Marlin Eric, Becker Ursula, Bee Valerie, Wilson Veronique, Legrand Catherine, Buyse Marc, A statistical approach to central monitoring of data quality in clinical trials, 10.1177/1740774512447898
  14. Desmet L., Venet D., Doffagne E., Timmermans C., Burzykowski T., Legrand C., Buyse M., Linear mixed-effects models for central statistical monitoring of multicenter clinical trials, 10.1002/sim.6294
  15. Timmermans C, Doffagne E, Venet D et al (2015) Using central statistical monitoring to assess data quality and consistency in the stomach cancer adjuvant multi-institutional group trial (SAMIT). In submission
  16. Desmet L, Venet D, Doffagne E et al (2015) Use of the beta-binomial model for central statistical monitoring of multicenter clinical trials. In submission
  17. Kirkwood Amy A, Cox Trevor, Hackshaw Allan, Application of methods for central statistical monitoring in clinical trials, 10.1177/1740774513494504
  18. Edwards Phil, Shakur Haleema, Barnetson Lin, Prieto David, Evans Stephen, Roberts Ian, Central and statistical data monitoring in the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial, 10.1177/1740774513514145
  19. Pogue Janice M, Devereaux PJ, Thorlund Kristian, Yusuf Salim, Central statistical monitoring: Detecting fraud in clinical trials, 10.1177/1740774512469312
  20. Al-Marzouki S., Are these data real? Statistical methods for the detection of data fabrication in clinical trials, 10.1136/bmj.331.7511.267
  21. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial, 10.1016/s0140-6736(99)11179-6
  22. Altman Douglas G, Randomisation in the SYMPHONY trial, 10.1016/s0140-6736(05)73268-2
  23. Newby L Kristin, Bhapkar Manju V, Lee Kerry L, Investigators Robert M Califf for the SYMPHONY, Randomisation in the SYMPHONY trial, 10.1016/s0140-6736(05)73269-4
  24. Peto Richard, Collins Rory, Sackett David, Darbyshire Janet, Babiker Abdel, Buyse Marc, Stewart Helen, Baum Michael, Goldhirsch Aron, Bonadonna Gianni, Valagussa Pinuccia, Rutqvist Lars, Elbourne Diana, Davies Christina, Dalesio Otilia, Parmar Mahesh, Hill Catherine, Clarke Michael, Gray Richard, Doll Richard, The trials of Dr. Bernard Fisher: A European perspective on an American episode, 10.1016/s0197-2456(96)00225-5
  25. European Stroke Prevention Study 2 Group (1997) European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 151(Suppl): S1–S77